Xiamen Humanity Hospital
Immunology and immunotherapy in China typically cost from $4,700 to $17,300. Total expenses depend on the specific therapy type, number of treatment cycles, and whether you choose public or private facilities. International patients often save 70-85% compared to the United States for advanced treatments.
Typical Immunology Costs in China
Major medical centers are concentrated in Beijing, Shanghai, and Guangzhou. While public hospitals offer lower base rates, private JCI-accredited facilities in Shanghai often provide specialized concierge services for international patients. Consult with a specialist to get accurate pricing for your specific diagnosis.
| China | Turkey | Austria | |
| Umbilical cord stem cell therapy | from $16,500 | from $5,000 | from $7,500 |
| Plasmapheresis | from $2,200 | from $1,200 | from $2,000 |
| Curcumin IV Therapy | from $350 | from $350 | from $350 |
| Therapeutic Apheresis | from $2,500 | from $1,350 | - |
| Selective Apheresis | from $3,500 | from $1,550 | - |
No hidden fees – just official clinic prices. Pay at the clinic for Immunology treatment upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Immunology treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Immunology treatment journey.
Professor Liang Xiaoxiao is the Department Director and Chief Physician in Neurorehabilitation. She holds a master’s degree in neurology. She is skilled in neuromodulation for disorders of consciousness, cognition, and movement. Her focus includes cases from cerebrovascular disease, Parkinson’s disease, and related conditions. She also performs ultrasound-guided botulinum toxin injections for blepharospasm, hemifacial spasm, limb spasticity, sialorrhea, and neuralgia.
Accreditations and roles: Member of the Neurorehabilitation, Cognitive Disorder Rehabilitation, and Craniocerebral Trauma Rehabilitation Committees of the Chinese Association of Rehabilitation Medicine. Standing Member of the Cognitive Disorder Rehabilitation Committee of the Fujian Association of Rehabilitation Medicine. Vice Chair of the Dementia and Cognitive Disorder Committee of the Xiamen Preventive Medicine Association. Vice President of the Parkinson’s Disease and Movement Disorders Committee of the Xiamen Medical Doctor Association. Standing Member of the Neuromodulation Committee of the Xiamen Medical Doctor Association. Recipient of the Most Beautiful Physician of Xiamen City (2024).
Professor Zheng Qiu Hong is Director of the Cell Therapy Research Center and a National Senior Expert in Biotherapy. He is a Professor and Master’s Supervisor at Fujian Medical University. He has more than 30 years of clinical experience in tumor molecular biology and biotherapy. From 2012 to 2013, he was a visiting scholar in stem cell research at the University of Connecticut School of Life Sciences. He previously held leadership roles at Fujian Cancer Hospital. These roles included Director of the Tumor Molecular Biology Laboratory and Director of the Surgical Oncology Research Laboratory. He also served as Deputy Director of the Fujian Key Laboratory of Tumor Biotherapy and Deputy Director of the Biotherapy and Immunotherapy Center.
Appointments include Standing Committee Member of the Biotherapy Committee of the Chinese Research Hospital Association. He is also a Committee Member of the Tumor Immunology and Biotherapy Committee of the Chinese Society for Immunology. In addition, he is Deputy Chair of the Academic Committee of the Xiamen Cell Therapy Research Center at the First Affiliated Hospital of Xiamen University.
Leading expert in traditional Chinese medicine with over 42 years of experience of experience treating chronic inflammatory conditions like vasculitis and Myasthenia at Yanda International Hospital.
China offers advanced immunotherapy including CAR-T cell therapy, immune checkpoint inhibitors, and combination treatments for international patients. Facilities like Yanda International Hospital integrate modern protocols with traditional approaches. Specialized centers in Beijing and Shanghai provide access to domestic PD-1 inhibitors and global clinical trials for various malignancies.
Bookimed Expert Insight: Data shows that Class A level 3 hospitals like Yanda International Hospital serve up to 2,500,000 patients annually. These high-volume centers often combine 28,500 modern technologies with traditional Chinese medicine to manage treatment side effects. This integrative approach is a unique differentiator for patients seeking holistic recovery support during intensive immunotherapy.
Patient Consensus: Patients emphasize that Beijing and Shanghai are the primary hubs for accessing PD-1 inhibitors. Many note that working with a bilingual medical agent is essential for navigating the hospital system and confirming trial slots.
Most international patients pay out-of-pocket for immunotherapy in China as Western insurance plans often exclude Asian networks. Public coverage is limited to legally employed residents contributing to social security. Major facilities like Yanda International Hospital and Xiamen Humanity Hospital typically require full upfront payments.
Bookimed Expert Insight: Data from Xiamen Humanity Hospital shows it is accredited for Phase I-IV drug trials. Patients often find that enrolling in these clinical trials is a reliable way to access new immunotherapies. This strategy can significantly reduce costs compared to private treatment which lacks standard insurance integration.
Patient Consensus: Patients note that Western insurance rarely covers elective care in China and suggest budgeting for full costs. Many recommend requesting itemized English invoices immediately to simplify the difficult manual reimbursement process after returning home.
Immunotherapy monotherapy is generally less effective for Chinese patients with EGFR-mutated lung cancer than those with wild-type tumors. Response rates for single-agent inhibitors range from 1.8% to 14%. Expert protocols in China prioritize combination therapies to overcome the cold tumor microenvironment common in these mutations.
Bookimed Expert Insight: While monotherapy underperforms, China's Class A Level III centers like Yanda International Hospital utilize advanced diagnostics to identify rare responders. Data shows that patients who are T790M-negative after initial therapy failure often see better results from these combinations. Facilities accredited for Phase I–IV trials, such as Xiamen Humanity Hospital, provide access to emerging protocols that combine next-gen inhibitors with immunotherapy.
Patient Consensus: Patients emphasize that starting immunotherapy alone often leads to rapid progression within 2 months. Many note that skipping straight to next-gen targeted therapies provides more stability than experimental immune combinations.
International patients can join immunotherapy clinical trials in China by searching the Chinese Clinical Trial Registry or ClinicalTrials.gov. Successful enrollment requires a formal invitation from a Good Clinical Practice-compliant hospital. Top centers in Beijing and Shanghai often lead these innovative Phase 1–4 drug studies.
Bookimed Expert Insight: Our data shows that high-volume centers like Yanda International Hospital, which serves 2,500,000 patients annually, often combine international protocols with local expertise. For clinical trials, focusing on tertiary hospitals in Beijing is strategic. These institutions have the highest concentration of JCI-accredited facilities and specialized research departments.
Patient Consensus: Patients note that while trials offer hope when Western options fail, having a local sponsor is vital. Many emphasize that navigating the process requires professional translation of medical records and a reliable VPN for daily coordination.
International patients typically use a standard L-visa or M-visa for immunotherapy in China. A hospital invitation letter is required for stays exceeding 30 days. Initial stays range from 30 to 90 days. Extensions up to 180 days are possible with medical justification from the treating facility.
Bookimed Expert Insight: High-volume centers like Yanda International Hospital, which serves 2,500,000 patients annually, have dedicated systems for international documentation. These JCI-accredited facilities often combine traditional Chinese medicine with international protocols. This integrated approach can simplify the medical justification needed for visa extensions at the Public Security Bureau.
Patient Consensus: Patients note that getting the hospital invitation letter early is vital for a smooth embassy application. Many suggest using the 144-hour visa-free transit for an initial consultation before committing to a long-term treatment plan.
Major Chinese immunotherapy centers in Beijing and Shanghai provide English-speaking staff and dedicated international departments. High-tier facilities like Yanda International Hospital hold JCI accreditation. These centers offer bilingual medical coordinators, visa support, and specialized VIP wings. Most senior oncologists have international training for direct English consultations.
Bookimed Expert Insight: Data shows a clear distinction between public wards and Class A level III clinics like Yanda International Hospital. While public hospitals are massive, serving 2,500,000 patients annually, English proficiency is often limited to their international medical centers. Choosing a facility with a dedicated international department ensures you avoid language barriers in nursing and administrative areas.
Patient Consensus: Patients note that while doctors are often fluent, nursing staff in general wards may not speak English. Many travelers recommend using WeChat groups for real-time translation and hiring a private medical interpreter as a backup for follow-up care.
China enforces rigid absolute contraindications for allergy immunotherapy that often exceed Western standards. Guidelines from the National Medical Products Administration (NMPA) include definitive age cut-offs and strict medication bans. These rules prioritise patient safety during subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT).
Bookimed Expert Insight: Major hubs like Yanda International Hospital combine JCI-accredited protocols with traditional medicine. This dual approach allows specialists to manage chronic inflammatory processes while following NMPA safety mandates. High-volume centres in Beijing and Xiamen frequently require a complete medication review. This ensures no ACE inhibitors or beta-blockers are present before starting therapy.
Patient Consensus: Patients note it is essential to confirm the clinic has on-site emergency facilities. Experience in China shows that pre-treatment screening for asthma control is the standard. This thorough process helps ensure a safe immunotherapy start.
China approved the first commercial CAR-T therapy for solid tumours, satri-cel (CT041), in early 2026. This treatment targets gastric and pancreatic cancers expressing the Claudin18.2 biomarker. Other solid tumours, such as liver and lung cancer, remain accessible through clinical trials.
Bookimed Expert Insight: China operates more investigator-initiated CAR-T trials than any other country. Large facilities like Xiamen Humanity Hospital treat 1,000,000 patients annually. These centres often integrate trials with nuclear medicine. Patients with solid tumours can access experimental protocols that are unavailable in most other regions.
Patient Consensus: Patients note that CAR-T for solid tumours in China is typically research-based. They advise verifying if a treatment is part of a registered clinical trial before travelling.
Chinese clinics provide several domestically developed immunotherapy drugs. These serve as direct alternatives to imported medications. These homegrown immune checkpoint inhibitors, such as Tislelizumab and Toripalimab, are widely used in hospitals. Facilities like Xiamen Humanity Hospital and Yanda International Hospital use them to treat various cancers.
Bookimed Expert Insight: Clinics that hold Class A level III status, such as Yanda International Hospital, often integrate traditional approaches with modern immunotherapy. This hybrid model helps patients manage treatment side effects while using domestic drugs. These major centres treat over 2,000,000 patients yearly. This gives doctors vast experience with these local alternatives.
Patient Consensus: Patients note it is important to request the exact drug leaflet and manufacturer name. Many Australians verify these local brand names with their specialists back home before starting therapy in China.
Natural Killer (NK) cell immunotherapy is safely combined with traditional chemotherapy in China. Clinical data indicates this combination is well-tolerated and often improves treatment results. Chinese research institutions report mild side effects like transient fatigue. Severe reactions like cytokine release syndrome (CRS) are rare.
Bookimed Expert Insight: Chinese oncology centres use modern technology to manage complex cases. Xiamen Humanity Hospital uses Varian VitalBeam and PET/CT for monitoring. These facilities treat patients from over 50 countries. High patient volumes, like Yanda's 2.5 million annual visitors, suggest deep clinical experience. Clinics with JCI accreditation often provide better support for international patients.
Patient Consensus: Patients note China offers modern equipment like the Da Vinci Surgical System. They emphasise confirming if treatments are part of formal clinical trials. Success often depends on how clinics monitor infection and liver function during combined therapy. Those seeking treatment in Beijing or Xiamen appreciate the blend of modern and traditional protocols.
Subcutaneous Immunotherapy (SCIT), commonly known as allergy shots, is the preferred method in Chinese clinics. Over 95% of Chinese allergists recommend this gold standard. It involves weekly injections during a build-up phase. Maintenance injections then continue for 3 to 5 years.
Bookimed Expert Insight: Major facilities like Yanda International Hospital in Beijing combine international protocols with traditional approaches. Large-scale centres treat up to 2,500,000 patients annually. This massive patient volume allows clinicians to refine dosing precision for common allergens like Artemisia. These centres often hold JCI accreditation for safety during the mandatory 30-minute post-injection observation period.
Patient Consensus: Patients note that methods vary by clinic in China. It is important to confirm whether a facility uses shots or oral drops. This is because dosing is highly individualised.
Patients typically stay in China for 7 to 14 days after standard immunotherapy cycles. Cell-based treatments like CAR-T therapy require 14 to 28 days of monitoring. This stay provides safety while immune-related reactions or complications like cytokine release syndrome are most likely.
Bookimed Expert Insight: Major centres like Yanda International Hospital serve 2,500,000 patients annually. International cases often require specific S2 visa extensions. If recovery takes longer than expected, JCI-accredited hospitals assist with converting medical visas into stay permits. This prevents legal issues for patients needing unexpected observation days after immune enhancement therapy.
Patient Consensus: Patients note that staying until the team confirms the next step is vital. Many recommend planning buffer days for extra blood work or scans before booking return flights.